Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bacterial outer membrane

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Bacterial outer membrane. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-002972-95 Sponsor Protocol Number: V72_74 Start Date*: 2014-12-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Phase 3b, Open label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults from 18 to 50 Y...
    Medical condition: Meningococcal Group B disease.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-005128-12 Sponsor Protocol Number: 208205 Start Date*: 2018-06-11
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase II, Randomized, Open-label, Multicenter Study to Assess the Immunogenicity and Safety of GSK Meningococcal MenABCWY Vaccine, and of GSK Meningococcal Group B and MenACWY Conjugate Vaccines ...
    Medical condition: Primary immunization against Neisseria meningitidis serogroups A, B, C, W-135, and Y.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-002451-15 Sponsor Protocol Number: V102_15 Start Date*: 2014-09-19
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK...
    Medical condition: The current study is designed to assess immunological non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to healthy adolescents 10 to 18 years of age, to those o...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002230-69 Sponsor Protocol Number: V102_15E1 Start Date*: 2016-10-31
    Sponsor Name:GlaxoSmithKline Biologicals S.A.
    Full Title: A Phase 2b, Open-Label, Multi-Center Study Assessing the Immunological Persistence of Antibodies at Approximately 2 years After the last Meningococcal Vaccination in Study V102_15 and the Response ...
    Medical condition: Meningococcal diseases
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005815-25 Sponsor Protocol Number: V72_59 Start Date*: 2013-07-09
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-Risk Adu...
    Medical condition: A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-Risk Adu...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001927-74 Sponsor Protocol Number: SysVac01-C60P2 (PA/2008/2883) Start Date*: 2009-01-16
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: A PHASE II, OPEN LABEL, RANDOMISED, TWO CENTRE STUDY TO EVALUATE THE IMPORTANCE OF NATURALLY INDUCED IMMUNE REGULATION ON THE MUCOSAL IMMUNE RESPONSE TO MENINGOCOCCAL SEROGROUP B OUTER MEMBRANE VES...
    Medical condition: "Healthy volunteers" In this project we will establish whether naturally induced mucosal CD25+ T regulatory activity in adults and adolescents modulates the mucosal immune response to systemic Me...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003937-41 Sponsor Protocol Number: V102_03E1 Start Date*: 2014-01-17
    Sponsor Name:GSK Vaccines S.r.l
    Full Title: Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Follow...
    Medical condition: This study will evaluate the safety and immunogenicity of a booster dose of MenABCWY vaccine; either MenABCWY+OMV or MenABCWY+1/4OMV, administered to adolescent and young adults who previously rece...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004476-30 Sponsor Protocol Number: V72_41 Start Date*: 2014-10-24
    Sponsor Name:Novartis Vaccines and Diagnostics SRL
    Full Title: A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis rMenB+OMV NZ Vaccine Formulated with Outer Membrane Vesicle (OMV) Manufactu...
    Medical condition: Prophylaxis against invasive meningococcal disease
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004982-42 Sponsor Protocol Number: 213171 Start Date*: 2021-02-08
    Sponsor Name:GlaxoSmithKline Biologics SA (GSK)
    Full Title: A phase IIIB, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of GSK’s meningococcal ABCWY vaccine when administered in healthy adolescents and adults, previously...
    Medical condition: Healthy volunteers (active immunization against invasive disease caused by N. meningitidis serogroups A, B, C, W and Y)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000657-30 Sponsor Protocol Number: V72_28E1 Start Date*: 2013-05-30
    Sponsor Name:Novartis Vaccines and Diagnostics s.r.l.
    Full Title: A Phase IIIB, Open Label, Multi-Center Extension Study of V72_28 to assess antibody persistence, and the safety and tolerability of a booster dose after the completion of the vaccination course in ...
    Medical condition: A phase IIIB, Open Label, Multi Center extension study of V72_28 to assess antibody persistence, and the safety and tolerability of a booster dose after the completion of the vaccination course in ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001367-24 Sponsor Protocol Number: 217043 Start Date*: 2021-11-16
    Sponsor Name:GlaxoSmithKline SA
    Full Title: A Phase II, randomized, partially blinded study to assess the safety, tolerability and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants.
    Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) DE (Trial now transitioned) PL (Trial now transitioned) IT (Completed) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004741-37 Sponsor Protocol Number: 212458 Start Date*: 2021-06-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase I/II, randomised, controlled study to assess the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine when administered to healthy adults (Phase I) and to healt...
    Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) Outside EU/EEA PL (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002454-78 Sponsor Protocol Number: V72_62 Start Date*: 2014-02-18
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase IIIb, Open Label, Controlled, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Novartis Meningococcal Group B Vaccine when administered to Immunoco...
    Medical condition: Meningococcal Group B disease.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003822-42 Sponsor Protocol Number: B1971048 Start Date*: 2015-01-30
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 4, Single-Arm, Open-Label Study describing the safety and immunogenicity of Bexsero in healthy subjects aged 12 years to <19 years.
    Medical condition: Test the safety and immunogenicity of Bexsero used as a vaccine for Neisseria meningitidis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-000979-27 Sponsor Protocol Number: V102_16 Start Date*: 2015-05-07
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolesc...
    Medical condition: Prophylaxis against invasive disease strains of N. meningitidis serogroup B.
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021528-81 Sponsor Protocol Number: V72_28 Start Date*: 2011-03-18
    Sponsor Name:Novartis Vaccines and Diagnostics s.r.l.
    Full Title: A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants Accordi...
    Medical condition: Estudio fase 3B, abierto y multicéntrico para evaluar la seguridad, tolerabilidad e inmunogenicidad de la vacuna meningocócica recombinante B de Novartis cuando se administra sola a bebés sanos seg...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027202 Meningitis bacterial LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-004931-30 Sponsor Protocol Number: V72P12E2 Start Date*: 2012-10-10
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fift Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who ...
    Medical condition: Prevention of meningococcal disease caused by serogroup B Neisseria meningitidis by evaluating the Antibody persistence in 4-year old healthy children who previously received the Novartis meningoco...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-003694-29 Sponsor Protocol Number: V72_37 Start Date*: 2013-03-26
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase 3b, Multi-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-risk Adults
    Medical condition: Healthy volunteers (Meningitis B)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004992-21 Sponsor Protocol Number: V72P10E1 Start Date*: 2014-11-28
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l
    Full Title: A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10.
    Medical condition: Prophylaxis against invasive meningococcal disease
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004410-29 Sponsor Protocol Number: V72P10 Start Date*: 2014-10-27
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l
    Full Title: A Phase 2b/3, Multi-Center, Observer-Blind, Controlled Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents Aged ...
    Medical condition: Prophylaxis against invasive meningococcal disease
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 20:17:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA